Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that
its collaborators from The University of Texas MD Anderson Cancer Center (“MD
Anderson”) presented positive preclinical data at the American Association of
Cancer Research Tumor Immunology and Immunotherapy Meeting 2019. According to
the update, the data shows positive results for the combination of TUSC2
immunogene therapy with an anti-PD1 antibody, pembrolizumab, and for the
combination of TUSC2 immunogene therapy, pembrolizumab, and chemotherapy for
the treatment of some of the most resistant metastatic lung cancers, including
the KRAS and LKB1 mutations. “These data not only further support existing
preclinical data showing that Oncoprex immunogene therapy is synergistic with
anti-PD1 therapy, but they also offer new data demonstrating that Oncoprex
improves on the combination of anti-PD1 therapy and chemotherapy, today’s first
line standard of care for lung cancer,” Genprex President and Chief Operating
Officer Julien L. Pham, MD, MPH, said in the news release. “In a sophisticated
humanized mouse model, the combination of TUSC2 with pembrolizumab and
carboplatin resulted in complete eradication of anti-PD1 resistant lung
metastases in some of the most resistant cancer mutations. This is highly
encouraging and provides us with a strong indication that the combination could
lead to similar results in the clinic.”
To view the full press release, visit http://ibn.fm/KNPGH
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients based
upon a unique proprietary technology platform. Genprex’s platform technologies
are designed to administer cancer-fighting genes by encapsulating them into nanoscale
hollow spheres called nanovesicles, which are then administered intravenously
and taken up by tumor cells where they express proteins that are missing or
found in low quantities. The company’s lead product candidate, Oncoprex(TM)
immunogene therapy for non-small cell lung cancer (“NSCLC”), has a multimodal
mechanism of action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes pathways for
apoptosis, or programmed cell death, in cancer cells, and modulates the immune
response against cancer cells. Oncoprex has also been shown to block mechanisms
that create drug resistance. For more information, visit the company’s website
at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
